Reply
- PMID: 33682325
- DOI: 10.1002/art.41711
Reply
Comment on
-
Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.Arthritis Rheumatol. 2021 Feb;73(2):212-222. doi: 10.1002/art.41516. Epub 2020 Dec 26. Arthritis Rheumatol. 2021. PMID: 32909363 Free PMC article.
-
Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al.Arthritis Rheumatol. 2021 Aug;73(8):1567-1569. doi: 10.1002/art.41712. Epub 2021 Jun 20. Arthritis Rheumatol. 2021. PMID: 33645925 No abstract available.
References
-
- Mellors T, Withers JB, Ameli A, Jones A, Wang M, Zhang L, et al. Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. Netw Syst Med 2020;3:91-104.
-
- Bienkowska JR, Dalgin GS, Batliwalla F, Allaire N, Roubenoff R, Gregersen PK, et al. Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response. Genomics 2009;94:423-32.
-
- Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness [review]. Health Technol Assess 2006;10:1-229.
-
- Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources